Frontiers in Oncology Seminars
Harnessing the Immune System to Treat Hodgkin Lymphoma and Primary Mediastinal B-cell Lymphoma
Margaret Shipp, MD
May 18, 2021
Dr. Margaret Shipp is Chief of the Division of Hematologic Neoplasia and Director of the Lymphoma Research Center at the Dana-Farber Cancer Institute. Dr. Shipp received her MD from Washington University School of Medicine, St. Louis, where she also did an internship and residency in Internal Medicine at Barnes Hospital. She completed a Medical Oncology fellowship at the Dana-Farber Cancer Institute and subsequently joined the faculty.
Dr. Shipp’s research interests include the characterization of comprehensive molecular signatures, survival pathways and associated rational therapeutic targets in aggressive B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), additional large B-cell lymphoma subtypes and classical Hodgkin lymphoma (cHL). The Shipp group has identified genetic bases of immune evasion in specific lymphoid malignancies and targeted these pathways in associated clinical trials. The group has defined recurrent 9p24.1 copy number alterations and associated overexpression of the PD-1 ligands as a genetic basis for
sensitivity of cHL and primary mediastinal large B-cell lymphoma (PMBL) to PD-1 blockade. Additionally, Dr. Shipp and colleagues have elucidated mechanisms of action of PD-1 blockade in cHL and PMBL which are largely MHC class I-negative tumors. The group has also developed a widely accepted genetic taxonomy of diffuse large B-cell lymphoma which includes five discrete subtypes with associated targets for therapy.